PRESENTATION

Q1 2020 — Presentation

Q1 2020PDF · 19 pages464 KB
Merck
1Q 2020 Earnings

-- 1 of 19 --

Forward-looking statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
2
This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe
harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements include statements with
respect to the company's plans to spinoff certain of its businesses into an independent company, the timing and structure of such spinoff, the
characteristics of the business to be separated, the expected benefits of the spin-off to the company and the expected effect on the company's
dividends. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant
risks and uncertainties. There can be no guarantees with respect to whether the proposed spinoff will be completed on the proposed timetable or at
all or with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially
successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth
in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and
currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry
regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability
to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent
litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2019
Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site
(www.sec.gov).

-- 2 of 19 --

$12.1B
+13%
Q1 performance highlights
3
Advanced
the
pipeline
1. Growth rates exclude impact of foreign exchange
2. The GAAP to non-GAAP reconciliation is available in the Supplemental Tables to Merck’s Q1 2020 earnings release.
3. GAAP EPS $1.26
Delivered
worldwide
sales
growth 1
• 	Returned $2.8 billion to shareholders through
dividends and share repurchases
• 	Continued commitment to value-enhancing
business development with spend of $2.6 billion
• 	Completed the acquisition of ArQule
$1.50
+26%
Drove
non-GAAP
EPS
growth 1
• 	Announced positive top-line results for phase 3 trials
of investigational gefapixant in chronic cough
•
•
Presented results from phase 3 VICTORIA trial
studying investigational vericiguat in patients with
worsening heart failure with reduced ejection fraction
Moved 5 early oncology assets into Phase 2
(MK-4280, MK-7684, MK-1454, MK-1308, MK-5890)
development and 1 into Phase 3 (MK-6482)
• Announced KEYTRUDA top-line results for two trials
including: positive PFS for KN-204 in cHL, positive
PFS for KN-355 in TNBC
• Received FDA approval for KEYTRUDA in NMIBC
based on KN-057
• Announced registration for ERVEBO in four African
nations: DRC, Burundi, Ghana and Zambia
Created
shareholder
value

-- 3 of 19 --

Oncology: continued strength & leadership across portfolio
• 	KEYTRUDA sales of $3.3B grew +46% year-
over-year
o 	In the U.S., sales of $1.9B were driven by all
key tumors and continued strengthening of
overall leadership position in I/O market
o 	+44% growth in international markets, as
lung continues to drive growth globally
• 	Oncology portfolio continues to benefit from
growth of Lynparza, +86%, and Lenvima, +73%
o 	Lynparza remains leading PARPi in the U.S.
o 	Lenvima maintains market leadership in HCC
in U.S., and is benefitting from strong
launch in combination with KEYTRUDA in EC
1. All growth rates exclude the impact of foreign exchange.
1Q19 	1Q20
KEYTRUDA Performance1
+46% YOY
4

-- 4 of 19 --

1Q19 	1Q20
Vaccines: growth driven by strong global demand
• 	Vaccines sales grew +16% year-over-year
• 	GARDASIL sales of ~$1.1B grew +33%,
benefitting significantly from timing of
shipments in China and timing of CDC
purchases in the U.S., which contributed
~$190M, partially offset by the impact of
COVID-19
• 	GARDASIL sales also reflect strong
underlying global demand
• 	PNEUMOVAX sales of ~$260M, +40%, also
contributed to growth, primarily due to
heightened interest in pneumococcal
vaccination amidst the COVID-19 pandemic
1. All growth rates exclude the impact of foreign exchange. 	5
+33% YOY
GARDASIL Performance1

-- 5 of 19 --

Hospital: BRIDION continues to drive global growth
1Q19 	1Q20
• 	BRIDION sales of ~$300M grew +19%,
driven by demand growth across all major
regions
• 	Continued success from launch of
PREVYMIS for CMV prophylaxis in certain
stem cell transplant recipients, with sales
of ~$60M, +90%
• 	Demonstrated commitment to the
development of novel antibiotics and
antivirals as highlighted by recent
approvals, acceptances and data readouts
1. All growth rates exclude the impact of foreign exchange.
+19% YOY
6
BRIDION Performance1

-- 6 of 19 --

Animal Health: innovative portfolio positioned for long-term success
1Q19 	1Q20
• 	Animal Health sales were ~$1.2B, +21%
• 	Increase in advance purchases amidst the
COVID-19 pandemic positively impacted the
Animal Health business by ~$60M
• 	Livestock, with sales of ~$740M, grew +24%,
largely benefitting from the contribution of
the Antelliq acquisition and the COVID-19
related buy-in
• 	Companion Animals, with sales of ~$475,
grew +17% driven by the BRAVECTO line
of products and the COVID-19 related buy-in
1. All growth rates exclude the impact of foreign exchange.
+21% YOY
7
Animal Health Performance1

-- 7 of 19 --

Global Human Health performance
United
States
Canada
Europe 2
Latin
America
Eastern Europe /
Middle East
Africa
Japan
+42%
1. All growth rates exclude the impact of foreign exchange.
2.Europe primarily represents all European Union countries and the European Union accession markets.
China
Global
pharmaceutical
sales +12%1
$343M
+12%
+20% 	+1%
+7%
+13%
+19%
Asia Pacific
-2%
8

-- 8 of 19 --

Q1 2020 financial results summary:
Delivered leveraged P&L with strong revenue and EPS growth
1. Net income attributable to Merck & Co., Inc.
2. Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and
trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses
performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information
prepared in accordance with GAAP.
Q1 2020 	Q1 2019 	Change Change
Ex-FX
Sales 	$12.1 	$10.8 	11% 	13%
GAAP net income 1 	$3.2 	$2.9 	10% 	13%
Non-GAAP net income
that excludes certain items 1, 2 	$3.8 	$3.2 	20% 	24%
GAAP EPS 	$1.26 	$1.12 	13% 	15%
Non-GAAP EPS that excludes
certain items 2 	$1.50 	$1.22 	23% 	26%
GAAP Gross Margin 	72.5% 	71.8% 	0.7pts 	1.1pts
Non-GAAP Gross Margin 2 	75.5% 	75.9% 	-0.4pts 	-0.1pts
$ in billions, except EPS amounts
9

-- 9 of 19 --

Balanced approach to capital allocation:
Investing in the business and creating value for shareholders
Capital Investments
2019 to 2023
~$ 19.0B
Over 5 years, including expanding manufacturing
capacity for Oncology, Vaccines, and Animal
Health. Includes >$10.0B in the U.S.
Over the Past 12 Months
$0
$1
$2
$3
$4
$5
$6
$7
$8
After-Tax R&D 	CapEx 	Dividends Paid 	Business
Development -
Ex Divestitures
Share
Repurchase (net
of Options
Proceeds)
$7.4
$3.9
$5.8 	$7.5 $4.8	
Billions
ORDER OF
PRIORITY
Commitment to the Dividend
$1.72 	$1.76 	$1.80 	$1.84 	$1.88 	$1.92
$2.20
$2.44
$1.40
$1.70
$2.00
$2.30
2013 	2014 	2015 	2016 	2017 	2018 	2019 	2020E
Dollars per share
+11% 	+2% 	+2% +2% 	+2% +2%
+11%
10
+15%
• 	$10.6 billion in dividend and share repurchases
o 	Remain committed to the dividend, which increased
11% in 2020
o 	Temporarily suspended share repurchase program;
returned $5.0 billion share repurchases (excluding
option proceeds)
• 	$9.0 billion invested in R&D ($7.4 billion after-tax)
• 	~$8 billion spent on over 80 transactions, including recently
closed ArQule acquisition
Balanced Capital Allocation to Return Cash to Shareholders
While Investing in Growth Over Past 12 Months

-- 10 of 19 --

Remain confident in long-term fundamental strength of business
11
Strong underlying patient
demand for our innovative
medicines and vaccines,
which address significant
unmet medical need
First quarter results demonstrate
underlying strength of the business
Operational and financial strength,
including our strong balance sheet, allows
us to execute on our key priorities
Clinical programs and timelines remain on
track
Strategic focus on innovation remains our
competitive advantage

-- 11 of 19 --

Merck is actively engaged in playing a role in
& finding solutions for the COVID-19 pandemic
12
R&D Efforts 	Relief Efforts 	Clinical Trials Manufacturing
and Supply
Facilities and
Employees
• 	Team of scientists
researching COVID-19 and
assessing our antiviral
candidates and vaccine
assets
• 	Thoughtful selection of
proven platforms that
have been used to
generate vaccines with
desirable qualities
• 	In discussions with
multiple groups, focusing
on three viral vaccine
platforms
• 	Engaged with a range of
external organizations,
including a research
collaboration with ISB and
the NIH-led ACTIV
partnership
• 	Supporting communities
through product & PPE
donations, and funding relief
organizations
• 	Provided 800,000 surgical
masks in NY and NJ
• 	Merck for Mothers donation
to help systems better meet
needs of pregnant women
• 	Enabling medically trained
employees to volunteer to aid
communities while
maintaining base pay
• 	Updating access and
assistance programs
• 	Continuity of clinical trials
was maintained in 1Q using
operational continuity plans
that were scaled regionally
as the pandemic spread
• 	Making every effort to
ensure patients in affected
areas enrolled in clinical trials
continue to receive
treatment, care, and
monitoring
• 	Conditions are fluid and
evolving, but as local
conditions allow, we are
enrolling patients in new and
ongoing studies
• 	To date, COVID-19 has not
had a material impact on the
production and supply of our
medicines and vaccines
• 	Continue to have normal
supply levels for most of our
products, including
KEYTRUDA and GARDASIL
• 	In general, Merck carries
several months of inventory
• 	We currently believe supply
of our medicines and vaccines
will remain at normal levels
throughout the pandemic
• 	Majority of manufacturing
sites are fully operational
and labs are focused on
essential operations
• 	Our office-based colleagues
are primarily working from
home
• 	In China, all of our offices,
labs and plants are now
open, though many
employees continue to work
from home
• 	In many markets, paused in-
person interactions with
HCPs, and field-based
employees are working
from home

-- 12 of 19 --

Key guidance assumptions: COVID-19
13
Patient
Access
Peak
Outbreak
Normalization 	Variability
• 	Reduced access to
hospitals and other
healthcare sites,
particularly those treating
COVID-19, resulting in
decreased patient visits
• 	Peak of the virus assumed
in the second quarter in
the U.S. and EU
• 	Current social distancing
measures in the U.S. and
EU to extend into June
• 	Anticipate gradual return
to normal operations
beginning late in the
second quarter and
through the third quarter
• 	Full return to normal
operations in the fourth
quarter
• 	These assumptions will
vary based on:
o 	Duration, spread
and severity of
outbreak
o 	Timing of return to
normal conditions

-- 13 of 19 --

Human Health commercial considerations: COVID-19
14
Oncology 	Vaccines 	Hospital 	Animal Health
• 	To prioritize patients based on
severity and the immediate
needs of different tumor
types, oncologists are delaying
appointments and procedures
• 	This may lead to delays in the
start of therapy for newly
diagnosed patients and
challenges in adhering to
dosing schedules for existing
patients.
• 	Professional recommendations
to further reinforce social
distancing measures leads to
delayed well visits
• 	Based on recommendations
from the AAP and
CDC, most pediatricians in the
U.S. have pushed out routine
immunization of all children
except those <24 months
• 	Non-urgent elective
procedures have been
postponed or canceled in most
markets in order to:
o 	Slow the spread of
disease
o 	Enable hospital
prioritization of COVID
patients
• 	Reduced veterinary visits and
decreased protein and milk
consumption due to
restaurant and school closures
will negatively impact volume
• 	Negative impacts on the
economy will have an
additional effect on the
business
Roughly two-thirds of our global Human Health revenue
is comprised of physician-administered products

-- 14 of 19 --

15
Oncology 	Vaccines 	Hospital 	Animal Health
• 	To prioritize patients based on
severity and the immediate
needs of different tumor
types, oncologists are delaying
appointments and procedures
• 	This may lead to delays in the
start of therapy for newly
diagnosed patients and
challenges in adhering to
dosing schedules for existing
patients.
• 	Professional recommendations
to further reinforce social
distancing measures leads to
delayed well visits
• 	Based on recommendations
from the AAP and
CDC, most pediatricians in the
U.S. have pushed out routine
immunization of all children
except those <24 months
• 	Non-urgent elective
procedures have been
postponed or canceled in most
markets in order to:
o 	Slow the spread of
disease
o 	Enable hospital
prioritization of COVID
patients
• 	Reduced veterinary visits and
decreased protein and milk
consumption due to
restaurant and school closures
will negatively impact volume
• 	Negative impacts on the
economy will have an
additional effect on the
business
Expect to experience a more protracted recovery
timeline from our Animal Health business
Animal Health commercial considerations: COVID-19

-- 15 of 19 --

Updated full-year 2020 guidance
1. GAAP Gross Margin Rate: In line with 2019
2. GAAP Operating Expenses: Lower than 2019 by a low-single digit rate
3. GAAP Tax Rate: ~16.5 – 17.5%
4 The GAAP to non-GAAP reconciliation is available in Merck’s Q1 2020 earnings release
Prior Guidance 	Updated Guidance 	Key Assumptions
Revenue $48.8B - $50.3B
+4% to +7% (+5% to +8% ex-FX)
$46.1B - $48.1B
-2% to +3% (+1% to +5% ex-FX)
• 	Assumes ~2.5% negative FX impact,
an incremental ~$750M headwind vs.
prior guidance
• 	Reflects assumed COVID-19 impacts
Non-GAAP
Gross Margin Rate 1 	~75.5% 	~75.0%
• 	Reduced due to higher anticipated
shipping costs, supplies, amortization
and inventory write-offs
Non-GAAP
Operating Expenses2 	Low single-digit rate increases 	Low single-digit rate decrease
• 	Reduced due to lower promotional and
selling costs, delayed clinical program
spend due to COVID-19, and FX
benefit
Other (Income) / Expense 	~$200M of other expense 	~$200M of other expense 	• 	No change
Tax Rate 3 	17.5% to 18.5% 	17.0% to 18.0% • 	Reflects favorable impact of earnings
mix in lower tax jurisdictions
Shares Outstanding 	~2.54B 	~2.54B • 	No change; reflects temporary pause
in share repurchases
GAAP EPS 4 	$4.57 to $4.72 	$4.14 to $4.29
Non-GAAP EPS 4 	$5.62 to $5.77
+8% to +11% (+10% to +13% ex-FX)
$5.17 to $5.37
0% to +4% (+3% to +7% ex-FX)
• 	Assumes ~3.5% negative FX impact,
an incremental ~$0.11 headwind vs.
prior guidance
• 	Reflects assumed COVID-19 impacts
16

-- 16 of 19 --

Progressing the spinoff of Organon & Co.
17
Announced Organon & Co. as the new
company name
• 	The Organon name has strong brand equity
and engenders great respect among
healthcare professionals for its dedication and
innovation in women’s health
Continued to make progress on building
out strong executive leadership team for
Organon & Co.
Rooted in our belief that two, more-
focused companies will drive stronger
growth and unlock long-term value for
patients and shareholders
Continue to expect spinoff
of Organon & Co. to be
completed in the first half
of 2021

-- 17 of 19 --

Creating long-term value for patients, employees and shareholders
Anchored by our deep bench of talent
and commitment to our mission
Next 5 Years
Strong execution driving
sustainable revenue growth,
meaningful margin expansion and
accelerated bottom-line growth
5-10 Years
Rich pipeline addressing
areas of high unmet need to
drive performance over the
next 5 to 10 years
10+ Years
Revitalized discovery efforts and
increased expertise in biology to
deliver ongoing scientific
breakthroughs for decades to come
18

-- 18 of 19 --

Corporate responsibility that creates sustainable value
Access to
Health
Employees
Environmental
Sustainability
Ethics and
Transparency
Earning trust and confidence of stakeholders is critical for a company in the business of marketing and selling
medicines and vaccines
• 	Demonstrated commitment to transparency through disclosures about our business and how we operate, including being first
pharmaceutical company to publish a multi-year report about pricing practices
• 	Work with broad range of stakeholders to help develop and advance innovative financing and payment models to improve access
• 	Integrating the SDGs into our reporting to demonstrate our commitment to sustainable development
Executing sustainability strategy to take advantage of opportunities to reduce environmental impact across operations and
supply chain
• 	Energy-conservation and water-use-reduction initiatives
• 	Reducing environmental impacts of new products, packaging, buildings and equipment
• 	Purchasing electricity from renewable energy sources to reduce greenhouse gas emissions
• 	Collaborating with suppliers and customers to address shared needs and interests in environmentally beneficial ways
Fostering diverse and gender-balanced workforce essential to performance as a research-intensive company and to attracting
most talented scientists
• 	Numerous programs to engage employees and promote positive work environment (including female mentorship by female Board members)
- 	51% of new hires in 2018 were female
- 	41% of management roles in 2018 held by women
- 	36% of new U.S. hires in 2018 were members of underrepresented ethnic groups
- 	21% of U.S. executive roles in 2018 were held by members of underrepresented ethnic groups
Increasing access to health advances Merck’s efforts to serve more patients
• 	Long history of making medicines and vaccines accessible and affordable through responsible pricing practices and industry-leading patient support programs
• 	Addressing 88% of the top 20 global burdens of disease with products and pipeline
• 	Merck for Mothers - $500 million initiative to prevent maternal deaths has reached more than 11 million women worldwide
• 	Our 30+ year old MECTIZAN® Donation Program for river blindness and lymphatic filariasis that is making progress to eliminate these diseases in endemic
countries: eliminated river blindness in 4 Latin American countries and in parts of 6 African countries so far, and we have eliminated lymphatic filariasis in 2 countries
in Africa and the Middle East
• 	ERVEBO, Merck’s vaccine for the prevention of disease caused by Zaire ebolavirus, is FDA approved (over 300,000 patients in the DRC vaccinated to-date with
investigational doses)
19

-- 19 of 19 --